Local therapy alone is associated with longer survival in selected oligometastatic renal cancer

In 72 matched pairs, initial local therapy without systemic treatment was associated with 73.0% versus 58.6% five-year survival, without improved PFS.

KEY POINTS

  • This retrospective single-center study evaluated 276 patients with oligometastatic renal cell carcinoma, defined as five or fewer metastatic lesions, following nephrectomy between 2015 and 2023. 173 patients received complete metastasis-directed therapy (MDT) without initial systemic therapy, while 103 received systemic therapy with or without local treatment. Exact matching on six clinical and prognostic variables generated 72 matched pairs.
  • Local therapy was predominantly surgical rather than radiation-based. Among the MDT-alone group, 78.6% underwent surgery alone, 12.1% received radiotherapy alone, and 9.2% received combined surgery and radiotherapy. In the systemic therapy group, 62.1% received tyrosine kinase inhibitor monotherapy, while only 29.1% received ICI-based combinations, limiting direct comparison with contemporary first-line immunotherapy regimens.
  • After matching, five-year overall survival was 73.0% with MDT alone versus 58.6% with systemic therapy-based management, an absolute difference of 14.4 percentage points (HR 0.45, 95% CI 0.26–0.77; p=0.004). Five-year cancer-specific survival was also higher with MDT alone (83.7% vs 69.8%; HR 0.35, 95% CI 0.18–0.67; p=0.001).
  • Despite the survival association, progression-free survival did not improve. Five-year PFS in the matched cohort was 16.3% with MDT alone versus 18.8% with systemic therapy (HR 1.11, 95% CI 0.77–1.61; p=0.579), and five-year distant metastasis-free survival was similarly comparable (20.7% vs 22.9%; HR 1.10; p=0.624). This discordance raises important uncertainty about whether the apparent survival advantage reflects treatment efficacy or unmeasured differences in disease biology and subsequent management.
  • Complete local therapy provided substantial local disease control: five-year local progression-free survival was 80.2% with MDT alone versus 44.8% with systemic therapy-based management in matched patients (HR 0.28; p<0.001). However, this endpoint inherently favored the group in which all detectable lesions were treated locally, whereas many patients receiving systemic therapy did not undergo complete metastasis ablation.
  • Systemic treatment could be deferred for prolonged periods in selected patients. Among all 173 MDT-alone patients, 86 (49.7%) eventually initiated systemic therapy, with a median observed interval of 22.9 months among those who started treatment. The cumulative incidence of systemic therapy initiation was 25.3% at two years and 48.6% at five years, while median systemic therapy-free survival was 53.0 months.
  • Exploratory radiation-dose analysis showed no local failures among 12 patients whose irradiated lesions all received BED10 ≥80 Gy, compared with 3/14 failures (21.4%) when at least one lesion received a lower dose; all three occurred at bone sites. These numbers are too small to establish a dose threshold, and radiation-treated patients had more adverse disease characteristics. More broadly, patients selected for MDT initially had more solitary metastases and favorable-risk disease, while bone involvement remained imbalanced after matching; treatment-related toxicity and quality of life were not systematically evaluated.

CLINICAL TAKEAWAY

Complete local treatment may be a reasonable systemic therapy-deferring strategy for carefully selected patients with oligometastatic RCC, particularly those with limited, indolent disease amenable to eradication. However, this study does not establish superiority over contemporary ICI-based systemic therapy, and because most MDT patients underwent surgery, its survival findings should not be presented as direct evidence that SBRT improves overall survival.

SOURCE

Radiotherapy and Oncology

Browse more research Suggest a correction